Instrumentation Laboratory Launches HemosIL® Direct Thrombin Inhibitor Assay in Europe for Measurement Of Dabigatran


-Direct Oral Anticoagulant Measurement, Automated on ACL TOP® Family of Hemostasis Testing Systems-



BEDFORD, Mass. - Instrumentation Laboratory (IL) today announced the commercialization in Europe of their HemosIL Direct Thrombin Inhibitor (DTI) Assay.  When used in conjunction with HemosIL Dabigatran Calibrators and Controls, this test offers an automated solution for the measurement of dabigatran, a direct oral anticoagulant (DOAC).  The assay, calibrators and controls are CE Marked.



With an extended linear range and very low limit of detection, the HemosIL DTI Assay with Dabigatran Calibrators and Controls provides unmatched technical performance for Hemostasis laboratories conducting dabigatran testing. This testing solution offers consistency and accuracy to help inform critical patient management decisions. Like other HemosIL assays, the DTI Assay is automated on the ACL TOPFamily of Hemostasis Testing Systems for exceptional efficiency.  Dabigatran etexilate (manufactured and marketed by Boehringer Ingelheim as Pradaxa® inhibits the action of thrombin to provide an anticoagulant effect in vivo. 



"With the growing use of DOACs around the world, the need to test for their presence and concentration has increased substantially," said Remo Tazzi, Director Worldwide Marketing, Hemostasis at IL. "The new DTI Assay addresses this critical need by providing an essential tool for patient management and epitomizes our responsiveness to customers and their dynamic healthcare environment."



HemosIL DTI is the first in a DOAC Assay Panel to be commercialized by IL.  The Company plans to introduce assays, calibrators and controls for other DOACs in the coming months. 



Although monitoring is not required for patients on DOAC therapy, there are exceptions when measurement may be beneficial.  Examples include patients who: present to the ER with an adverse event; require immediate reversal of anticoagulation; experience renal or liver failure; have suspected or known interaction with other drugs; require verification of pre-operative drug clearance.



Instrumentation Laboratory Launches HemosIL® Direct Thrombin Inhibitor Assay in Europe for Measurement of Dabigatran



Today, IL is the #1 manufacturer of instruments and reagents for the hemostasis market worldwide.  For decades, the Company has been at the forefront of innovation in hemostasis testing, culminating in the release of their ACL TOP Family of Hemostasis Testing Systems.  This line of fully automated analyzers is the leading Hemostasis testing product line in the world.



Instrumentation Laboratory (www.ilus.com), founded in 1959, is a worldwide developer, manufacturer and distributor of in vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The company's product lines include Critical Care systems, Hemostasis systems and Information Management systems. IL's GEM® product offerings, part of the Critical Care line, include the GEM Premier(TM) 4000 analyzer with Intelligent Quality Management (iQM®), GEM Premier 3500, GEMweb® Plus Custom Connectivity, and complementary products GEM PCL Plus, a portable coagulation analyzer, GEM OPL CO-Oximeter, and GEMdraw arterial blood samplers. IL's Hemostasis portfolio includes the ACL TOP® Family of Hemostasis Testing Systems, fully automated, high-productivity analyzers, comprised of the ACL TOP 700, ACL TOP 700 LAS, ACL TOP 700 CTS, ACL TOP 500 CTS and ACL TOP 300 CTS.  IL also offers the ACL AcuStar®, ACL ELITE®, and other Hemostasis analyzers, along with the comprehensive HemosIL® line of reagents.  IL is based in Bedford, Massachusetts. 



The Instrumentation Laboratory logo, GEM, iQM, HemosIL, ACL TOP, ACL ELITE, ACL AcuStar and Premier are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies, and may be registered in the United States Patent and Trademark Office and in other jurisdictions.  All other product names, company names, marks, logos, and symbols are trademarks of their respective owners.



PRADAXA® is a registered trademark of Boehringer Ingelheim Pharma GmbH Co. KG and used under license.



Source

Instrumentation Laboratory



Contact: Sally McCraven, Instrumentation Laboratory, smccraven@ilww.com



Web Site: www.ilus.com

More from Optics & Photonics

All Topics